vs
Side-by-side financial comparison of EASTERN CO (EML) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $55.3M, roughly 1.9× EASTERN CO). EASTERN CO runs the higher net margin — 1.0% vs -29.4%, a 30.5% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -22.4%). EASTERN CO produced more free cash flow last quarter ($3.1M vs $-34.8M).
EASTERN COEMLEarnings & Financial Report
China Eastern Airlines is a major airline in China, headquartered in Changning, Shanghai. It is one of the three major airlines in the country, along with Air China and China Southern Airlines.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
EML vs TWST — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $55.3M | $103.7M |
| Net Profit | $578.9K | $-30.5M |
| Gross Margin | 22.3% | 52.0% |
| Operating Margin | 3.1% | -31.7% |
| Net Margin | 1.0% | -29.4% |
| Revenue YoY | -22.4% | 16.9% |
| Net Profit YoY | 103.8% | 3.4% |
| EPS (diluted) | $0.10 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q3 25 | $55.3M | — | ||
| Q2 25 | $70.2M | — | ||
| Q1 25 | $63.3M | — | ||
| Q4 24 | $64.3M | — | ||
| Q3 24 | $71.3M | — | ||
| Q2 24 | $72.6M | — | ||
| Q1 24 | $64.6M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $578.9K | — | ||
| Q2 25 | $3.4M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $-15.3M | — | ||
| Q2 24 | $3.5M | — | ||
| Q1 24 | $1.9M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 22.4% | — | ||
| Q4 24 | 23.6% | — | ||
| Q3 24 | 25.5% | — | ||
| Q2 24 | 25.4% | — | ||
| Q1 24 | 23.9% | — |
| Q4 25 | — | -31.7% | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | 3.1% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | -21.5% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.0% | — |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.56 | — | ||
| Q1 25 | $0.32 | — | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $-2.46 | — | ||
| Q2 24 | $0.56 | — | ||
| Q1 24 | $0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.2M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $124.3M | $456.1M |
| Total Assets | $220.0M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | $9.2M | — | ||
| Q2 25 | $9.1M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | $16.1M | — | ||
| Q3 24 | $9.7M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $42.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $456.1M | ||
| Q3 25 | $124.3M | — | ||
| Q2 25 | $124.4M | — | ||
| Q1 25 | $121.0M | — | ||
| Q4 24 | $120.7M | — | ||
| Q3 24 | $119.2M | — | ||
| Q2 24 | $136.5M | — | ||
| Q1 24 | $134.5M | — |
| Q4 25 | — | $638.1M | ||
| Q3 25 | $220.0M | — | ||
| Q2 25 | $229.4M | — | ||
| Q1 25 | $232.3M | — | ||
| Q4 24 | $235.3M | — | ||
| Q3 24 | $244.2M | — | ||
| Q2 24 | $255.9M | — | ||
| Q1 24 | $253.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.1M | $-24.8M |
| Free Cash FlowOCF − Capex | $3.1M | $-34.8M |
| FCF MarginFCF / Revenue | 5.5% | -33.5% |
| Capex IntensityCapex / Revenue | 0.1% | 9.6% |
| Cash ConversionOCF / Net Profit | 5.38× | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $11.0M | — | ||
| Q3 24 | $-2.9M | — | ||
| Q2 24 | $8.4M | — | ||
| Q1 24 | $2.8M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $9.0M | — | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $1.1M | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | -4.3% | — | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | -10.8% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 2.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 5.38× | — | ||
| Q2 25 | 1.09× | — | ||
| Q1 25 | -0.95× | — | ||
| Q4 24 | 8.41× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.40× | — | ||
| Q1 24 | 1.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EML
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
